TTM
$3.56
YoY change
-178.2%
5Y CAGR
—
Peak year (2009)
$5.37
Latest annual
$3.45
EPS (Diluted) history chart for Bristol-Myers Squibb (BMY) from 1987 to 2025
Latest: $3.45
EPS (Diluted) growth chart for Bristol-Myers Squibb (BMY) from 1987 to 2025
Latest: -178.2%
EPS (Diluted) history table for Bristol-Myers Squibb (BMY) from 1987 to 2025
| 2025 | $3.45 | -178.2% | +$7.86 | ||
| 2024 | −$4.41 | -214.2% | −$8.27 | ||
| 2023 | $3.86 | +30.8% | +$0.91 | ||
| 2022 | $2.95 | -5.4% | −$0.17 | ||
| 2021 | $3.12 | -178.4% | +$7.10 | ||
| 2020 | −$3.98 | -298.0% | −$5.99 | ||
| 2019 | $2.01 | -33.7% | −$1.02 | ||
| 2018 | $3.03 | +396.7% | +$2.42 | ||
| 2017 | $0.61 | -77.0% | −$2.04 | ||
| 2016 | $2.65 | +173.2% | +$1.68 | ||
| 2015 | $0.97 | -19.2% | −$0.23 | ||
| 2014 | $1.20 | -22.1% | −$0.34 | ||
| 2013 | $1.54 | +32.8% | +$0.38 | ||
| 2012 | $1.16 | -46.3% | −$1.00 | ||
| 2011 | $2.16 | +20.0% | +$0.36 | ||
| 2010 | $1.80 | -66.5% | −$3.57 | ||
| 2009 | $5.37 | +105.0% | +$2.75 | ||
| 2008 | $2.62 | +140.4% | +$1.53 | ||
| 2007 | $1.09 | +34.6% | +$0.28 | ||
| 2006 | $0.81 | -46.4% | −$0.70 | ||
| 2005 | $1.51 | +24.8% | +$0.30 | ||
| 2004 | $1.21 | -23.9% | −$0.38 | ||
| 2003 | $1.59 | +55.9% | +$0.57 | ||
| 2002 | $1.02 | -61.8% | −$1.65 | ||
| 2001 | $2.67 | +13.1% | +$0.31 | ||
| 2000 | $2.36 | +14.6% | +$0.30 | ||
| 1999 | $2.06 | +32.9% | +$0.51 | ||
| 1998 | $1.55 | -1.3% | −$0.02 | ||
| 1997 | $1.57 | +12.1% | +$0.17 | ||
| 1996 | $1.40 | +57.3% | +$0.51 | ||
| 1995 | $0.89 | -1.1% | −$0.01 | ||
| 1994 | $0.90 | -5.3% | −$0.05 | ||
| 1993 | $0.95 | -1.0% | −$0.01 | ||
| 1992 | $0.96 | -3.0% | −$0.03 | ||
| 1991 | $0.99 | +17.9% | +$0.15 | ||
| 1990 | $0.84 | +133.3% | +$0.48 | ||
| 1989 | $0.36 | -40.0% | −$0.24 | ||
| 1988 | $0.60 | +20.0% | +$0.10 | ||
| 1987 | $0.50 | — | — |
- 2025$3.45-178.2%
- 2024−$4.41-214.2%
- 2023$3.86+30.8%
- 2022$2.95-5.4%
- 2021$3.12-178.4%
- 2020−$3.98-298.0%
- 2019$2.01-33.7%
- 2018$3.03+396.7%
- 2017$0.61-77.0%
- 2016$2.65+173.2%
- 2015$0.97-19.2%
- 2014$1.20-22.1%
- 2013$1.54+32.8%
- 2012$1.16-46.3%
- 2011$2.16+20.0%
- 2010$1.80-66.5%
- 2009$5.37+105.0%
- 2008$2.62+140.4%
- 2007$1.09+34.6%
- 2006$0.81-46.4%
- 2005$1.51+24.8%
- 2004$1.21-23.9%
- 2003$1.59+55.9%
- 2002$1.02-61.8%
- 2001$2.67+13.1%
- 2000$2.36+14.6%
- 1999$2.06+32.9%
- 1998$1.55-1.3%
- 1997$1.57+12.1%
- 1996$1.40+57.3%
- 1995$0.89-1.1%
- 1994$0.90-5.3%
- 1993$0.95-1.0%
- 1992$0.96-3.0%
- 1991$0.99+17.9%
- 1990$0.84+133.3%
- 1989$0.36-40.0%
- 1988$0.60+20.0%
- 1987$0.50—
EPS (Diluted) values are taken from Bristol-Myers Squibb's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EPS (Diluted) at Bristol-Myers Squibb (BMY)
According to Bristol-Myers Squibb's latest reported financial statements, the company's current diluted EPS (TTM) is $3.56. Diluted earnings per share (EPS) is net income divided by the diluted weighted-average shares outstanding over the period. It expresses profit on a per-share basis — the figure investors use to value an individual share — and accounts for potential dilution from options, RSUs, and convertible securities.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Bristol-Myers Squibb (BMY) most recent annual diluted EPS stands at $3.45 (2025) – plunged 178.2% year-over-year.
Through 2015–2025 (10 years), Bristol-Myers Squibb diluted EPS delivered a +13.5% annualised rate; with mixed annual results across the window.
Bristol-Myers Squibb diluted EPS peaked at $5.37 in 2009; the latest annual figure is $3.45 in 2025 (35.8% below peak).
Across the available history, diluted EPS reached its high of $5.37 in 2009 and its low of −$4.41 in 2024.
Bristol-Myers Squibb EPS (Diluted) by Year
Bristol-Myers Squibb EPS (Diluted) 2025: $3.45
2025's diluted EPS for Bristol-Myers Squibb came in at $3.45, plunged 178.2% below 2024.
Bristol-Myers Squibb EPS (Diluted) 2024: −$4.41
Bristol-Myers Squibb posted diluted EPS of −$4.41 in 2024, plunged 214.2% below 2023. This figure represents the lowest annual value in the available history.
Bristol-Myers Squibb EPS (Diluted) 2023: $3.86
In 2023, Bristol-Myers Squibb reported diluted EPS of $3.86, surged 30.8% from 2022.
Bristol-Myers Squibb EPS (Diluted) 2022: $2.95
Bristol-Myers Squibb diluted EPS in 2022 was $2.95, declined 5.4% below 2021.
Bristol-Myers Squibb EPS (Diluted) 2021: $3.12
Bristol-Myers Squibb diluted EPS in 2021 was $3.12.
See more financial history for Bristol-Myers Squibb (BMY). Or calculate EPS yourself.
Sector peers by EPS (Diluted)
Healthcare peers of Bristol-Myers Squibb (BMY), ranked by their latest diluted EPS
| $22.95 | |
| $14.23 | |
| $13.23 | |
| $11.03 | |
| $7.28 | |
| $6.54 | |
| $3.59 | |
| $2.37 |
- $22.95
- $14.23
- $13.23
- $11.03
- $7.28
- $6.54
- $3.59
- $2.37
Frequently asked questions
Bristol-Myers Squibb (BMY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation